Novartis has announced its biologic Cosentyx (secukinumab) was superior to AbbVie’s blockbuster Humira (adalimumab) in psoriatic arthritis (PsA) endpoints of the EXCEED head-to-head trial.

The primary endpoint of the EXCEED study was a 20% improvement in disease activity as defined by American College of Rheumatology (ACR20) at week 52 in three of five criteria: patient global assessment, physician global assessment, health assessment questionnaire, visual analogue pain scale, and erythrocyte sedimentation rate or C-reactive protein.

Although Cosentyx did not reach statistical significant superiority in ACR20, it was statistically higher than Humira in other PsA-specific endpoints, including Psoriasis Area and Severity Index (PASI)-90, ACR50. Detailed data will be presented at an upcoming medical meeting.

Investigator of the Cosentyx clinical trial programme and University of Glasgow professor of rheumatology Iain McInnes said: “These data will be welcomed by patients and clinicians to guide clinical decision making and highlight secukinumab as a viable option as a first-line biologic for the treatment of psoriatic arthritis.

Novartis global development head of immunology, hepatology and dermatology Eric Hughes said: “EXCEED is the first ever monotherapy head-to-head trial with a primary endpoint in psoriatic arthritis specific to joints.

“Novartis continues to reimagine care for patients and advance science in rheumatology. We will assess the EXCEED data in their totality and we view the results as confirming our vision of Cosentyx becoming standard of care in psoriatic arthritis.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the EXCEED trial, Cosentyx’s safety profile was consistent with previous studies of the biologic; no new safety signals for Cosentyx were detected.

Cosentyx is a human interleukin-17A (IL-17A) antagonist approved to treat plaque psoriasis, PsA and ankylosing spondylitis; it is approved in 65 countries for PsA, including China, the European Union and the US.

Earlier this year, Eli Lilly announced its Taltz (ixekizumab) outperformed Humira in PsA. The primary endpoint in the study was ACR50 and complete skin clearance as measured by PASI-100. Taltz also inhibitors IL-17, whereas Humira is a tumour necrosis factor inhibitor and so has a different mechanism of action.